About Stratatech Corp
Stratatech Corp is a company based in United States founded in 2000 was acquired by Mallinckrodt Pharmaceuticals in August 2016. Stratatech Corp has raised $3.68 million across 23 funding rounds from investors including Mallinckrodt Pharmaceuticals, HHS and National Cancer Institute. The company has 47 employees as of December 31, 2015. Stratatech Corp operates in a competitive market with competitors including Ilya Pharma, QBiotics, MediWound, Resolution Therapeutics and SanuWave, among others.
- Headquarter United States
- Employees 47 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.68 M (USD)
in 23 rounds
-
Latest Funding Round
$26 M (USD), Grant
Sep 29, 2018
-
Investors
Mallinckrodt Pharmaceuticals
& 7 more
-
Employee Count
47
as on Dec 31, 2015
-
Acquired by
Mallinckrodt Pharmaceuticals
(Aug 10, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Stratatech Corp
Stratatech Corp has successfully raised a total of $3.68M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $26 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Stratatech Corp
Stratatech Corp has secured backing from 8 investors, including institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Research and health information on diabetes and kidney diseases are provided by NIDDK.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Stratatech Corp
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stratatech Corp
Investment portfolio details for Stratatech Corp
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Stratatech Corp
Detailed financials for Stratatech Corp
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stratatech Corp Comparisons
Peer comparison for Stratatech Corp
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stratatech Corp
Stratatech Corp operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ilya Pharma, QBiotics, MediWound, Resolution Therapeutics and SanuWave, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Enzymatic therapies for tissue repair and regeneration are developed.
|
|
| Locked | Locked | Locked |
Macrophage cell therapies are developed for inflammatory and liver diseases.
|
|
| Locked | Locked | Locked |
Noninvasive devices and biologics for wound healing are developed.
|
|
| Locked | Locked | Locked |
Regenerative biomaterials for wounds are developed using particle technology.
|
Detailed competitors of Stratatech Corp
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stratatech Corp
Complete news archive for Stratatech Corp
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stratatech Corp
Stratatech Corp was founded in 2000 and raised its 1st funding round 3 years after it was founded.
Stratatech Corp is headquartered in United States.
Stratatech Corp is a funded company, having raised a total of $3.68M across 23 funding rounds to date.
As of Dec 31, 2015, the latest employee count at Stratatech Corp is 47.
Stratatech Corporation is a regenerative medicine company focused on the commercialization of unique, proprietary skin substitute products for therapeutic and research uses. The company flagship product StrataGraft skin tissue is a temporary wound cover that promotes wound healing by the patients own cells and improve the wound bed to receive autografts The Biomedical Advanced Research and Development Authority has awarded a contract valued at up to 247M for development of StrataGraft skin tissue.
Stratatech Corp's top competitors include Ilya Pharma, SanuWave and QBiotics.
Stratatech Corp has 8 investors. Key investors include Mallinckrodt Pharmaceuticals, HHS, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, and NIAID.